Related Experiment Videos
Hormonal therapy of breast cancer with special reference to Masteril therapy
Abstract:
From 1968 to 1972, a trial of a new agent, drostanolone propionate (Masteril), was conducted. This agent was tested against oophorectomy in a group of premenopausal patients, against nandrolone phenylpropionate (Durabolin) in a perimenopausal group, and against ethinyl oestradiol in a postmenopausal group. In the premenopausal group, 44% responded to Masteril and 22% to oophorectomy. In the perimenopausal group, 34,5% responded to Masteril and 39% to Durabolin. In the postmenopausal group, 57% responded to oestrogens and 38,5% to Masteril. The side-effects of Masteril are generally not serious and rarely contra-indicate its use. Masteril has been shown to be a useful and safe agent for all age groups, even though it may appear to be less effective than oestrogens in the postmenopausal patients.
Insights
Drostanolone propionate (Masteril) showed promise as a safe and useful agent across menopausal stages. While effective, it was less potent than oestrogens in postmenopausal patients but demonstrated good results in premenopausal and perimenopausal groups.
Area of Science:
- Endocrinology
- Oncology
- Pharmacology
Background:
- Hormone replacement therapy is crucial for managing menopausal symptoms.
- Anabolic-androgenic steroids (AAS) have been explored for therapeutic applications.
- Drostanolone propionate (Masteril) is an AAS with potential clinical uses.
Purpose of the Study:
- To evaluate the efficacy and safety of drostanolone propionate (Masteril) compared to established treatments.
- To assess Masteril's effectiveness across different menopausal stages: premenopausal, perimenopausal, and postmenopausal.
Main Methods:
- A clinical trial conducted from 1968 to 1972.
- Masteril was compared against oophorectomy (premenopausal), nandrolone phenylpropionate (perimenopausal), and ethinyl oestradiol (postmenopausal).
- Response rates and side-effects were recorded for each treatment group.
Main Results:
- In premenopausal patients, 44% responded to Masteril versus 22% to oophorectomy.
- In perimenopausal patients, 34.5% responded to Masteril versus 39% to nandrolone phenylpropionate.
- In postmenopausal patients, 38.5% responded to Masteril versus 57% to ethinyl oestradiol.
- Masteril exhibited generally mild and rarely contraindicating side-effects.
Conclusions:
- Drostanolone propionate (Masteril) is a useful and safe agent for patients across all menopausal stages.
- Masteril demonstrated efficacy in premenopausal and perimenopausal groups.
- While effective, Masteril appeared less potent than oestrogens in postmenopausal patients.